2 / 16
Page 66
Notes:
allied
academies
Ophthalmol Case Rep 2017 Volume 1 Issue 1
August 21-23, 2017 | Toronto, Canada
EYE AND VISION
3
rd
International Conference on
T
his study is to test if corneas treated with combined
verteporfin non-thermal laser therapy can increase
corneal mechanical stiffness and increase resistance to
enzymatic degradation. Human research corneas were
obtained from Tissue Bank International (Baltimore,
Maryland) and from North Carolina Eye Bank (Winston-
Salem, North Carolina). Riboflavin 5’-phosphate sodium salt
hydrate, 20% (w/w) dextran solution (from Leuconostoc
mesenteroides) and collagenase A (from Clostridium
histolyticum, E.C. 3.4.24.3) were obtained from Sigma
Aldrich (St. Louis, Missouri). Barron R artificial anterior
chambers were purchased from Katena Eye Instruments
(Denville, New Jersey). The VEGA LED-based UV emitter was
purchased from Costruzione Strumenti Oftalmici (Firenze,
Italy). Untreated corneas were dissolved in collagenase A
in 5.47 h ± 0.21 hours. Cross-linked corneas demonstrated
a slower rate of dissolution (20.06 h ± 1.23hours). We report
for the first time that verteporfin non-thermal photodynamic
laser increases corneal mechanical stiffness and resistance
to enzymatic collagenase degradation. Although a clinical
study of this methodology in human patients is still
needed, our results suggest that verteporfin non-thermal
photodynamic laser induces crosslinking cornea tissue that
is like collagen crosslinking (CXL) using ultraviolet-A (UVA)
irradiation combined with riboflavin. V-NLT could represent
an alternative treatment for cornea ectatic diseases.
e:
dr.salehalageel@gmail.comCornea crosslinking with verteporfin nonthermal laser therapy
Saleh. A. Al-Ageel
Prince sultan medical city, Saudi Arabia